Cost of sales, excluding amortization and impairment of acquired intangible assets
Breakdown
Segments
Clinical InventoryView metric
Product revenue, netView metric
Royalty and other revenueView metric
SPINRAZAView metric
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $358.4M | $468.2M | $399.9M | $462.2M | $415M | $384M | $326M | $478.7M |
| Royalty and other revenue | $187.6M | $170.5M | $183.6M | $167.1M | $190M | $290.4M | $169.5M | $182.3M |
| Clinical Inventory | $46M | $2.5M | — | $5.98M | $5.98M | $5.98M | $5.98M | $56.8M |
| SPINRAZA | $54.03M | $54.03M | $54.03M | $53.08M | $53.08M | $53.08M | $53.08M | — |
| Total | $546M | $638.7M | $583.5M | $629.3M | $605M | $674.4M | $495.5M | $661M |
SPINRAZA is derived from annual filings.